173 related articles for article (PubMed ID: 9472824)
1. Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.
Howell RW; Goddu SM; Rao DV
Med Phys; 1998 Jan; 25(1):37-42. PubMed ID: 9472824
[TBL] [Abstract][Full Text] [Related]
2. Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides.
Howell RW; Goddu SM; Rao DV
J Nucl Med; 1994 Nov; 35(11):1861-9. PubMed ID: 7965170
[TBL] [Abstract][Full Text] [Related]
3. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides.
Rao DV; Howell RW
J Nucl Med; 1993 Oct; 34(10):1801-10. PubMed ID: 8410301
[TBL] [Abstract][Full Text] [Related]
4. A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained.
Abou-Jaoudé W; Dale R
Cancer Biother Radiopharm; 2004 Jun; 19(3):308-21. PubMed ID: 15285877
[TBL] [Abstract][Full Text] [Related]
5. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
6. Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives.
Chen Z; Nath R
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):825-34. PubMed ID: 12573770
[TBL] [Abstract][Full Text] [Related]
7. Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters.
Hamacher KA; Sgouros G
Med Phys; 2001 Sep; 28(9):1857-74. PubMed ID: 11585217
[TBL] [Abstract][Full Text] [Related]
8. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.
Armpilia CI; Dale RG; Coles IP; Jones B; Antipas V
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):378-85. PubMed ID: 12527051
[TBL] [Abstract][Full Text] [Related]
9. [Influence of time-dose-relationships in therapeutic nuclear medicine applications on biological effectiveness of irradiation: consequences for dosimetry].
Oehme L; Dörr W; Wust P; Kotzerke J
Nuklearmedizin; 2008; 47(5):205-9. PubMed ID: 18852927
[TBL] [Abstract][Full Text] [Related]
10. Effect of tumour shrinkage on the biological effectiveness of permanent brachytherapy implants.
Dale RG; Jones B; Coles IP
Br J Radiol; 1994 Jul; 67(799):639-45. PubMed ID: 8061998
[TBL] [Abstract][Full Text] [Related]
11. A strategy to reduce red marrow dose for intraperitoneal radioimmunotherapy.
Macey DJ; Meredith RF
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3044s-3047s. PubMed ID: 10541341
[TBL] [Abstract][Full Text] [Related]
12. Marrow toxicity of 33P-versus 32P-orthophosphate: implications for therapy of bone pain and bone metastases.
Goddu SM; Bishayee A; Bouchet LG; Bolch WE; Rao DV; Howell RW
J Nucl Med; 2000 May; 41(5):941-51. PubMed ID: 10809212
[TBL] [Abstract][Full Text] [Related]
13. Theoretical study of the influence of a heterogeneous activity distribution on intratumoral absorbed dose distribution.
Bao A; Zhao X; Phillips WT; Woolley FR; Otto RA; Goins B; Hevezi JM
Med Phys; 2005 Jan; 32(1):200-8. PubMed ID: 15719971
[TBL] [Abstract][Full Text] [Related]
14. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
Gagne NL; Leonard KL; Rivard MJ
Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
[TBL] [Abstract][Full Text] [Related]
15. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.
O'Donoghue JA; Bardiès M; Wheldon TE
J Nucl Med; 1995 Oct; 36(10):1902-9. PubMed ID: 7562062
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
Uusijärvi H; Bernhardt P; Ericsson T; Forssell-Aronsson E
Med Phys; 2006 Sep; 33(9):3260-9. PubMed ID: 17022220
[TBL] [Abstract][Full Text] [Related]
17. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
18. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu H; Jain RK; Baxter LT
J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
[TBL] [Abstract][Full Text] [Related]
19. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
20. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
